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Prostate cancer is the most frequently diagnosed malignancy and
the second leading cause of cancer-related deaths of men in
Western industrialized countries. Androgen withdrawal remains the
only effective form of systemic therapy for men with advanced
disease, with symptomatic and/or objective response in 80% of the
patients. Progression to androgen-independence, however, occurs
within a few years in the majority of these cases (Denis and
Murphy, 1993). Despite several hundred clinical studies of 
both experimental and approved chemotherapeutic agents,
chemotherapy has limited antitumour activity with an objective
response rate of less than 10% and no demonstrated survival
benefit in advanced disease (Oh and Kantoff, 1998). Therefore,
androgen-independent (AI) disease is the main obstacle to
improving the survival and quality of life in patients with advanced
prostate cancer, and the means to enhance the efficacy of cytotoxic
chemotherapy for patients with advanced disease is required. 
Progression to androgen-independence is a complex process
including various combinations of clonal selection, adaptive up-
regulation of antiapoptotic genes, androgen receptor transactiva-
tion in the absence of androgen or increased levels of co-activators
and alternative growth factor pathway (Tang and Porter, 1997).
The association between these mechanisms and chemoresistant
phenotype of prostate cancer remains unclear. Furthermore,
although recent phase II reports using chemotherapeutic agents
are documenting improved response rates in hormone-refractory
disease (Hudes et al, 1995; Tannock et al, 1996; Kantoff et al,
1999), it has not been well analysed whether the efficacy of such
agents is enhanced, if they are administered earlier to achieve
synergistic or additive effects with androgen withdrawal. 
To date, controlled study of the complex process associated with
progression to androgen-independence has been difficult due to a
lack of an ideal animal model that mimics the clinical course of the
disease in men. Of the available human prostate cancer cell lines,
only the LNCaP cell line is androgen-dependent (AD), prostate-
specific antigen (PSA) secreting and immortalized in vitro. As in
human prostate cancer, serum PSA levels in the LNCaP tumour
model are initially regulated by androgen, directly proportional to
tumour volume, and increase after prolonged periods following
castration to progression to androgen-independence. Apoptotic
tumour regression does not consistently occur after castration, but
tumour growth is inhibited. Moreover, the serum PSA levels
decrease by 80% for several weeks after castration, after which
LNCaP tumour growth rates increase with the loss of androgen-
regulated PSA gene expression as a surrogate end-point of AI
progression (Gleave et al, 1999; Miyake et al, 2000a). Therefore,
this model is particularly useful to test the efficacy of agents
targeting castration-induced apoptosis and their effects on time to
AI progression. 
In this study, we first characterized the effects of combined
androgen ablation and cytotoxic chemotherapy on the apoptotic
features in LNCaP cells. Subsequently, the effect of the varied
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Summary Although numerous chemotherapeutic agents have been evaluated for patients with advanced prostate cancer, none have
demonstrated improved survival benefits. Here, in order to determine whether the efficacy of chemotherapy can be enhanced by changing the
regimen, we evaluated the effect of the varied timing and dosage of chemotherapy in combination with androgen withdrawal on time to
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their increase in serum PSA levels were significantly inhibited by the simultaneous injection of mitoxantrone with castration, compared to the
administration of mitoxantrone 2 weeks before or after castration. The TUNEL staining revealed that apoptotic cell death was extensively
induced in LNCaP tumours treated with simultaneous castration and mitoxantrone compared to tumours treated with the other schedules.
Furthermore, nude mice bearing LNCaP tumours were injected with a total of 0.5 mg mitoxantrone divided into 2, 5 and 10 days, with the most
significant therapeutic effect and delayed AI progression observed in mice given injection of mitoxantrone for 2 days. These findings suggest
that this might be the optimal way to perform cytotoxic chemotherapy and androgen withdrawal simultaneously in patients with advanced
prostate cancer and to administer chemotherapeutic agents at high dosage within short intervals. © 2001 Cancer Research Campaign
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on time to AI progression in the LNCaP tumour model was evalu-
ated in order to determine whether the efficacy of chemotherapy
can be enhanced by changing its regimen. 
MATERIALS AND METHODS 
Tumour cell line 
LNCaP cells were kindly provided by Dr LWK Chung (University
of Virginia, Charlottesville, Virginia, USA) and maintained in
RPMI 1640 (Life Technologies Inc, Gaithersburg) supplemented
with 5% heat-inactivated fetal calf serum. Steroid hormone-
depleted charcoal-stripped media (CSM) was prepared as de-
scribed previously (Miyake et al, 2000b). 
Chemotherapeutic agent 
Mitoxantrone was purchased from Wyeth-Ayerst Inc (Montreal,
Canada). Stock solutions of mitoxantrone (1 mg m–1) were
prepared with dimethyl sulfoxide (DMSO), and diluted with PBS
to the required concentrations prior to each in vitro experiment. 
In vitro cell growth assays 
The in vitro growth of LNCaP cells were assessed by the in vitro
mitogenic assay as described previously (Miyake et al, 2000b).
Briefly, 3 ´ 103 cells were seeded in each well of 96-well
microtitre plates and allowed to attach overnight. After treatment
with mitoxantrone, LNCaP cells were fixed with 1% glutaralde-
hyde (Sigma Chemical Co, St Louis) and stained with 0.5% crystal
violet (Sigma Chemical Co) The optical density was determined
with a microculture plate reader (Becton Dickinson Labware,
Lincoln Park) at 540 nm. Absorbance values were normalized to
the values obtained for the vehicle-treated cells to determine the
percent of survival. Each assay was performed in triplicate. 
DNA fragmentation analysis 
The nucleosomal DNA degradation was analysed as described
previously with a minor modification (Miyake et al, 2000c).
Briefly, 1 ´ 105 cultured cells were seeded in 5-cm culture dishes
and allowed to adhere overnight. After indicated treatment with
0.01 mM mitoxantrone, cells were harvested and then lysed in a
solution containing 100 mM NaCl, 10 mM Tris pH 7.4, 25 mM
EDTA, and 0.5% SDS. After centrifugation, the supernatants were
incubated with 300 mg ml–1 proteinase K for 5 h at 65˚C and
extracted with phenol-chloroform. The aqueous layer was treated
with 0.1 volume of 3 M sodium acetate, and the DNA was precipi-
tated with 2.5 volumes of 95% ethanol. Following treatment with
100 mg ml-–1 RNase A for 1 h at 37˚C, the sample was electro-
phoresed on a 2% agarose gel and stained with ethidium bromide. 
Assessment of in vivo LNCaP tumour growth and
determination of serum PSA levels 
One million LNCaP cells were inoculated subcutaneously with
0.1 ml of Matrigel (Becton Dickinson Labware) in the flank region
of 6- to 8-week-old male athymic nude mice (BALB/c strain;
CLEA Japan Inc, Tokyo). In the first set of experiments, 0.05 mg
mitoxantrone was administered once daily by intravenous injec-
tion into each nude mouse for 5 continuous days. When tumours
reached about 200 mm3 in volume, mice were randomly selected
for administration of mitoxantrone from 2 weeks before castration
(group 1), the day of castration (group 2), 2 weeks after castration
(group 3) or no treatment with mitoxantrone as the control (group
4). In the second set of experiments, a total of 0.5 mg mito-
xantrone was administered by intravenous injection into each nude
mouse. When tumours reached about 200 mm3 in volume, mice
were castrated and randomly selected for administration of
0.25 mg mitoxantrone from the day of castration to 1 day after
castration (group 1), 0.1 mg from the day of castration to 4 days
after castration (group 2), or 0.05 mg from the day of castration to
9 days after castration (group 3). Each experimental group
consisted of eight mice. 
Mice were castrated via a scrotal approach, and tumour volume
was measured once weekly and calculated by the formula length ´
width ´ depth ´ 0.5236 as described previously (Miyake et al,
2000a). Blood samples were obtained with tail-vein incisions of
mice once weekly. Serum PSA levels were determined by an enzy-
matic immunoassay kit with a lower limit of sensitivity of 0.2 mg l–1
(Abbott IMX, Montreal) according to the manufacturer’s protocol.
Data points were reported as mean values with standard deviation. 
TUNEL staining 
A modified TUNEL technique was used to detect apoptotic cells
in LNCaP tumours using the ApopTag In situ Apoptosis Detection
System (Oncor, Gaithersburg) according to the manufacture’s pro-
tocol. The number of positively stained cells per high-power field
in five random fields was counted and averaged. 
RESULTS 
Synergistic effect of mitoxantrone and androgen
ablation on induction of apoptosis in LNCaP cells 
To determine whether androgen ablation enhances the cytotoxic
effect of mitoxantrone on LNCaP cells, we treated LNCaP 
cells with various doses of mitoxantrone maintained in standard
medium or CSM, and the in vitro mitogenic assays were
performed to evaluate the cell viability. As shown in Figure 1A,
androgen ablation with the use of CSM-enhanced mitoxantrone
chemosensitivity in a dose-dependent manner, reducing the IC50 of
mitoxantrone by more than 50%. 
The DNA fragmentation assay was performed to analyse the
effect of treatment with sublethal dose of mitoxantrone maintained
in standard medium or CSM on induction of apoptotic cell death.
The characteristic apoptotic DNA ladder was observed only after
treatment with mitoxantrone in CSM (Figure 1B). 
Cytotoxic effects of mitoxantrone on LNCaP cells
according to the timing of androgen ablation 
To assess the optimal timing of chemotherapy, the in vitro
mitogenic assays were used to examine the viabilities of LNCaP
cells at the pre-, simultaneous- or post-use of mitoxantrone with
CSM. As shown in Figure 2, simultaneous use of LNCaP cells
with mitoxantrone and CSM achieved the most remarkable
growth-inhibitory effect among these three treatment schedules;
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of mitoxantrone by approximately 50% compared to other treat-
ment schedules. 
Effects of mitoxantrone therapy on LNCaP tumour
growth according to the timing of castration 
We then evaluated the efficacy of mitoxantrone treatment for
inhibiting the growth of subcutaneous LNCaP tumours according
to the timing of castration. Male mice bearing LNCaP tumours
were randomly selected for mitoxantrone treatment from 2 weeks
before castration (group 1), the day of castration (group 2), 2
weeks after castration (group 3) or no treatment with mitoxantrone
(group 4). Figures 3A and 3B illustrate the changes in mean
LNCaP tumour volumes and serum PSA levels, respectively. 
Consistent with our in vitro studies, mitoxantrone achieved 
the most significant inhibition of the LNCaP tumour growth, when
administered simultaneously with castration. By 12 weeks after
castration, the tumour volumes in groups 1, 3 and 4 increased
2-, 1.5- and 4-fold, respectively, above the tumour volume in group
2. As shown in Figure 3B, changes in serum PSA levels almost
paralleled changes in tumour volume; that is, by 12 weeks after
castration, serum PSA in groups 1, 3 and 4 reached 2-, 2- and 4.5-
fold above baseline PSA level before castration, respectively,
compared with 20% lower than precastrate baseline in group 2.
Furthermore, the TUNEL staining using tumour tissues harvested 4
weeks after castration revealed that apoptotic cell death was exten-
sively induced in LNCaP tumours in group 2 compared to other
groups. Apoptotic cells in group 2 detected by the TUNEL staining
were 3-, 2- and 9-fold higher than those in group 1, 3 and 4, respec-
tively (Figure 3C). 
Effects of the interval and dosage of mitoxantrone
therapy on LNCaP tumour growth 
To determine the optimal dosage, male mice bearing LNCaP
tumours were injected with a total of 0.5 mg mitoxantrone divided
into 2 (i.e. 0.25 mg daily, group 1), 5 (i.e. 0.1 mg daily, group 2)
and 10 days (i.e. 0.05 mg daily, group 3) from the day of castra-
tion. As shown in Figure 4A, intensive administration of mito-
xantrone achieved the most significant antitumour activity. By 12
weeks postcastration, the mean tumour volumes in group 2 and 3
reached 1.5- and 2-fold above the tumour volume in group 1,
respectively. Changes in serum PSA levels showed similar pattern
to those in tumour volume; that is, by 12 weeks after castration, the
mean serum PSA increased 1.2- and 1.5-fold above precastrate
levels in group 2 and 3, respectively, compared with remaining
60% lower than precastrate level in group 1 (Figure 4B). 
DISCUSSION 
Prostate cancers are considered to be a heterogeneous complex of
AD and AI cells, which explains the temporary control of prostate
Chemotherapy and androgen ablation for prostate cancer 861
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Figure 1 (A) Effect of mitoxantrone on proliferation of LNCaP cells
maintained in standard media (SM) or charcoal-stripped media (CSM). Cell
viability was determined by the in vitro cell growth assay. Each point
represents the mean of triplicate analyses with standard deviation. ** and *
differ from the cells maintained in SM (P < 0.01 and P < 0.05, respectively)
by Student’s t-test. (B) DNA fragmentation analysis of LNCaP cells
maintained in SM or CSM after treatment with mitoxantrone 
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Figure 2 Effect of mitoxantrone on LNCaP cells according to the timing of
androgen ablation. LNCaP cells were maintained in standard media (SM) for
48 h. The SM was then replaced with charcoal-stripped media (CSM) for 48 h,
and the CSM was finally replaced with SM for 48 h. In addition, the cells were
treated with various concentrations of mitoxantrone for 48 h before the use of
CSM (pre-treatment), at the same period as the use of CSM (simultaneous-
treatment) or after the use of CSM (post-treatment). Following 96 h of
incubation, cell viability was determined by the in vitro cell growth assay. Each
point represents the mean of triplicate analyses with standard deviation. 
* differs from the other treatment groups (P < 0.05) by Student’s t-testcancer with androgen-withdrawal therapy. A possible explanation
for progression to androgen-independence is that continuous
suppression of AD cells will ultimately lead to an overgrowth 
of cells that are not sensitive to androgen ablation (Tang and
Porter, 1997). To overcome androgen unresponsiveness, different
regimens using both experimental and/or approved chemother-
apeutic agents have been explored, however, to date, no chemother-
apeutic agent has demonstrated improved survival in patients with
advanced prostate cancer (Oh and Kantoff, 1998), emphasizing the
need for novel therapeutic approaches to achieve more favourable
effects than the current conventional regimen. 
Mitoxantrone is an anthracenedione that has demonstrated
inhibitory activity in a variety of malignancies, including prostate
cancer (Tannock et al, 1996; Kantoff et al, 1999). It is a drug that is
well suited for patients with advanced prostate cancer, because it
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Figure 4 Effects of mitoxantrone therapy on LNCaP tumour growth
according to the timing of castration. (A) A total of 0.5 mg mitoxantrone was
administered by intravenous injection into each nude mouse bearing LNCap
tumour. When tumours reached about 200 mm3 in volume, mice were
castrated and randomly selected for administration of 0.25 mg mitoxantrone
from the day of castration to 1 day after castration (group 1), 0.1 mg from the
day of castration to 4 days after castration (group 2), 0.05 mg from the day of
castration to 9 days after castration (group 3). Each data point represents the
mean tumour volume in each experiment with standard deviation * differs
from the other treatment groups (P < 0.01) by Student’s t-test. (B) Changes
in serum PSA levels in mice injected with the LNCaP cells. Each point
represents the mean PSA level in each experimental group with standard
deviation. ** and * differ from the other treatment groups (P < 0.01 and
P < 0.05, respectively) by Student’s t-test
Figure 3 Effects of mitoxantrone therapy on LNCaP tumour growth
according to the timing of castration. (A) Mice bearing LNCaP tumours were
randomly selected for administration of mitoxantrone from 2 weeks before
castration (group 1), the day of castration (group 2), 2 weeks after castration
(group 3) or no treatment with mitoxantrone as the control (group 4). Each
data point represents the mean tumour volume in each experimental group
with standard deviation.** and * differ from the other treatment groups
(P < 0.01 and P < 0.05, respectively) by Student’s t-test. (B) Changes in
serum PSA levels in mice injected with the LNCaP cells. Each point
represents the mean PSA level in each experimental group with standard
deviation.* differs from the other treatment groups (P < 0.01) by Student’s
t-test. (C) Four weeks after castration, LNCaP tumours were harvested from
each treatment group for the detection of apoptosis using TUNEL staining.
The number of positively stained cells per high power field in five random
fields was counted and averaged. * differs from the other treatment groups
(P < 0.01) by Student’s t-testcauses relatively modest toxicity. In fact, recent phase II reports
using mitoxantrone have documented improved response rates
in hormone-refractory disease (Hudes et al, 1995; Tannock et al,
1996; Kantoff et al, 1999). Based on these studies, the Food and
Drug Administration recently approved mitoxantrone for pallia-
tive treatment of hormone-refractory prostate cancer. However,
mitoxantrone as a second-line treatment modality has been
reported to be of only limited value in improving survival. There-
fore, in the present study, using the AD human prostate LNCaP
tumour model, we attempted to determine whether it is possible
to achieve more favourable effects by directly combining
mitoxantrone and androgen-withdrawal therapies. 
We first demonstrated that mitoxantrone-induced apoptosis into
LNCaP cells is synergistically enhanced by androgen ablation with
the use of CSM, and this synergistic effect becomes most remark-
able when LNCaP cells were simultaneously treated with mito-
xantrone and CSM. Similar to the results of in vitro studies,
LNCaP tumour growth in vivo and the increase in serum PSA
levels were significantly suppressed by the simultaneous injection
of mitoxantrone with castration compared to the administration of 
mitoxantrone before or after castration. Extensive apoptosis was
demonstrated by the TUNEL staining in LNCaP tumours treated
with simultaneous castration and mitoxantrone compared to
tumours treated with mitoxantrone before or after castration.
Furthermore, the second set of in vivo studies revealed that the
efficacy of simultaneous mitoxantrone and androgen withdrawal
therapy is notable by the administration of mitoxantrone at a
higher dosage within shorter interval. 
To date, the efficacy of chemotherapy, either as a single agent or
in combination therapy, has been traditionally evaluated in patients
with hormone-refractory disease (Oh and Kantoff, 1998), and when
used in this end-stage setting, none have demonstrated improved
survival. A more rational strategy to improve survival by delaying
emergence of the AI phenotype would initiate treatment earlier to
enhance castration-induced apoptosis rather than the conventional
approach of treating patients with established hormone-refractory
disease. To achieve more powerful antitumour effect, it would also
be important to administer chemotherapeutic agents intensively in a
short period. Although the addition of chemotherapeutic agent to
androgen ablation for newly-diagnosed prostate cancer has failed
to demonstrate improvement of survival and quality of life in the
clinical setting (Miyake et al, 1996; de Reijke et al, 1999), our
present experimental results suggest the usefulness of intensive
mitoxantrone therapy with simultaneous androgen withdrawal as a
primary therapy for advanced prostate cancer.
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